Srinivasan Ramanathan

Summary

Affiliation: Gilead Sciences
Country: USA

Publications

  1. doi request reprint Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, California 94404, USA
    Clin Pharmacokinet 50:229-44. 2011
  2. doi request reprint Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents
    Srinivasan Ramanathan
    Clinical Research, Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 64:45-50. 2013
  3. doi request reprint Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 53:209-14. 2010
  4. ncbi request reprint Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 45:274-9. 2007
  5. ncbi request reprint Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects
    Srinivasan Ramanathan
    Gilead Sciences Inc, Foster City, CA 94404, USA
    J Clin Pharmacol 46:559-66. 2006
  6. ncbi request reprint Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir
    Srinivasan Ramanathan
    Gilead Sciences, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 46:160-6. 2007
  7. ncbi request reprint Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Ther 13:1011-7. 2008
  8. doi request reprint Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
    Calvin Cohen
    Gilead Sciences Inc, Foster City, California, USA
    AIDS 25:F7-12. 2011
  9. ncbi request reprint Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration
    Brian P Kearney
    Gilead Sciences Inc, 333 Lakeside Drive, Foster City, CA 94404, USA
    J Clin Pharmacol 45:935-40. 2005

Detail Information

Publications9

  1. doi request reprint Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, California 94404, USA
    Clin Pharmacokinet 50:229-44. 2011
    ....
  2. doi request reprint Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents
    Srinivasan Ramanathan
    Clinical Research, Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 64:45-50. 2013
    ..The effects of various representative acid-reducing agents on the pharmacokinetics (PK) of boosted elvitegravir were evaluated by 1-way interaction in 4 studies...
  3. doi request reprint Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 53:209-14. 2010
    ..The pharmacokinetic (PK) interaction between ritonavir-boosted elvitegravir (elvitegravir/r) and maraviroc was evaluated...
  4. ncbi request reprint Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 45:274-9. 2007
    ..To evaluate the potential for clinically relevant drug-drug interaction between emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and the ritonavir-boosted HIV integrase inhibitor GS-9137 (GS-9137/r)...
  5. ncbi request reprint Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects
    Srinivasan Ramanathan
    Gilead Sciences Inc, Foster City, CA 94404, USA
    J Clin Pharmacol 46:559-66. 2006
    ..These results indicate that coadministration of tenofovir disoproxil fumarate and ribavirin does not result in substantial changes to their individual pharmacokinetic profiles...
  6. ncbi request reprint Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir
    Srinivasan Ramanathan
    Gilead Sciences, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 46:160-6. 2007
    ....
  7. ncbi request reprint Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Ther 13:1011-7. 2008
    ....
  8. doi request reprint Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
    Calvin Cohen
    Gilead Sciences Inc, Foster City, California, USA
    AIDS 25:F7-12. 2011
    ..To assess the safety and efficacy of two, single-tablet regimens for the initial treatment of HIV infection...
  9. ncbi request reprint Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration
    Brian P Kearney
    Gilead Sciences Inc, 333 Lakeside Drive, Foster City, CA 94404, USA
    J Clin Pharmacol 45:935-40. 2005
    ..These results demonstrate that coadministration of tenofovir disoproxil fumarate and adefovir dipivoxil does not result in substantial changes to their individual pharmacokinetic profiles...